Bionomics anticancer compound well tolerated
01 June, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) will use this week's ASCO meeting to present results of trials showing that the phase II dose level of BNC105 is safe and well-tolerated.
New York investment mission makes final preparations
31 May, 2012 by AusBiotechAusBiotech is about to host the ‘Australian Life Science Investment Showcase: New York 2012’ prior to the BIO 2012 convention (Boston).
Immuron progressing product pipeline
31 May, 2012 by Dylan Bushell-EmblingImmuron's (ASX:IMC) top leadership has acknowledged the company's flagging share price, but believe it does not reflect progress made developing two new products.
Terry White to stock Cellmid hair growth line
31 May, 2012 by Dylan Bushell-EmblingTerry White Chemists has become first pharmacy chain to agree to stock the Evolis hair growth product developed by Cellmid subsidiary Advangen.
Phylogica hits new milestone in Pfizer project
31 May, 2012 by Dylan Bushell-EmblingPerth-based Phylogica (ASX:PYC) will soon receive the second milestone payment in its peptide drug discovery collaboration with Pfizer.
Mark Harvey to focus on driving life science investment with AusBiotech
31 May, 2012 by Tim DeanAusBiotech’s newest board member, Dr Mark Harvey, aims to help drive investment into Australia’s life science sector.
Comment: Patent cliff revenues fertilise generics companies
31 May, 2012 by Staff WritersPharmaceutical companies might be scrambling, but the patent cliff is a boon for generics manufacturers around the world, says GlobalData’s Dr Jerry Isaacson
BioDiem teams for US research on eye disease
30 May, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has entered a collaboration with US researchers for pre-clinical studies into using its compound to fight retinitis pigmentosa.
AusBiotech announces new Board appointment
29 May, 2012 by AusBiotechAusBiotech today announced the appointment of Dr Mark Harvey to its Board, to join the leadership team of AusBiotech in its efforts to grow and attract capital to the biotechnology industry.
QRxPharma granted US patent for MoxDuo
28 May, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has been issued a key US patent for its MoxDuo pain formulation, extending its IP protection for the product until 2023.
Bionomics launches ovarian cancer trial
25 May, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has commenced a phase I/II trial of its BNC105 compound in ovarian cancer patients.
Applications now open for expanded prestigious science awards
24 May, 2012 by Staff WritersMinister for Innovation, Services and Small Business Louise Asher has announced applications are open for the 2012 Victoria Prize for Science and Innovation, and the 2012 Victoria Fellowships.
Brand Australia wants your success stories
24 May, 2012 by AusBiotechThe Building Brand Australia Program is designed around sourcing the best possible examples of contemporary Australian capability to show to the rest of the world.
Phosphagenics taps Labtec for pain patch design
24 May, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has enlisted the aid of Germany's Labtec to help design the final version of drug delivery patch TPM/oxycodone, ahead of phase III trials.
Alchemia cancer trial cleared to continue
23 May, 2012 by Dylan Bushell-EmblingThe DSMB overseeing Alchemia's (ASX:ACL) phase III trial of HA-Irinotecan in metastatic colorectal cancer has recommended that recruitment continue.
